Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.

Cardiovasc Res

Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's and Royal Papworth Hospitals, Cambridge CB2 0QQ, UK.

Published: September 2021

Pulmonary arterial hypertension (PAH) is estimated to affect between 10 and 50 people per million worldwide. The lack of cure and devastating nature of the disease means that treatment is crucial to arrest rapid clinical worsening. Current therapies are limited by their focus on inhibiting residual vasoconstriction rather than targeting key regulators of the cellular pathology. Potential disease-modifying therapies may come from research directed towards causal pathways involved in the cellular and molecular mechanisms of disease. It is widely acknowledged that targeting reduced expression of the critical bone morphogenetic protein type-2 receptor and its associated signalling pathways is a compelling therapeutic avenue to explore. In this review, we highlight the advances that have been made in understanding this pathway and the therapeutics that are being tested in clinical trials and the clinic to treat PAH.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479804PMC
http://dx.doi.org/10.1093/cvr/cvaa350DOI Listing

Publication Analysis

Top Keywords

pulmonary arterial
8
arterial hypertension
8
approaches treat
4
treat pulmonary
4
hypertension targeting
4
targeting bmpr2
4
bmpr2 cell
4
cell membrane
4
membrane nucleus
4
nucleus pulmonary
4

Similar Publications

Advanced Markers for Hemodynamic Monitoring in Cardiogenic Shock and End-Stage Heart Failure: A Mini Review.

Heart Fail Rev

January 2025

Division of Cardiovascular Medicine, University of Utah Health & School of Medicine, 30 N Mario Capecchi Drive, HELIX Building 3rd Floor, Salt Lake City, UT, 84112, USA.

Right heart catheterization (RHC) provides critical hemodynamic insights by measuring atrial, ventricular, and pulmonary artery pressures, as well as cardiac output (CO). Although the use of RHC has decreased, its application has been linked to improved outcomes. Advanced hemodynamic markers such as cardiac power output (CPO), aortic pulsatility index (API), pulmonary artery pulsatility index (PAPi), right atrial pressure to pulmonary capillary wedge pressure ratio (RAP/PCWP) and right ventricular stroke work index (RVSWI) have been introduced to enhance risk stratification in cardiogenic shock (CS) and end-stage heart failure (HF) patients.

View Article and Find Full Text PDF

Multisociety endorsement of the 2024 European guideline recommendations on coronary revascularization.

J Thorac Cardiovasc Surg

January 2025

Coronary Center, Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular, & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address:

View Article and Find Full Text PDF

Background: Ventricular fibrillation (VF) is a vicious arrhythmia usually generated after removal of the aortic cross-clamp (ACC) in patients undergoing open-heart surgery, which could damage cardiomyocytes, especially in patients with left ventricular hypertrophy (LVH). Amiodarone has the prominent properties of converting VF and restoring sinus rhythm. However, few studies concentrated on the effect of amiodarone before ACC release on reducing VF in patients with LVH.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!